Basilea Pharmaceutica Ltd. Logo
 
Home
 
 
Search
 
 
 

Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions.

 
News
 
 
Language
 
Thursday, January 24. 2019
 
Basel, Switzerland, January 24, 2019 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of Basilea's derazantinib and Roche's PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in patients with urothelial cancer. Basilea expects to start a biomarker-driven multi-cohort phase 1/2 study mid-2019.
 
more...
 
Wednesday, January 09. 2019
 
  • 21% objective response rate with six confirmed partial responses from 29 evaluable patients
  • 83% disease control rate
  • Safety profile and tolerability of continuous dosing schedule confirmed
 
more...
 
Monday, January 07. 2019
 
Basel, Switzerland, January 07, 2019 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the unaudited preliminary revenue for the financial year 2018. Total revenue is expected to increase by 31% over 2017 to approx. CHF 133 million (FYR 2017: CHF 101.5 million), with contributions of approx. CHF 82 million (FYR 2017: CHF 52.5 million, + 56%) from Basilea's two marketed products, the antifungal Cresemba® (isavuconazole) and the antibiotic Zevtera® (ceftobiprole). Basilea had guided for total revenue of CHF 120-130 million and contributions from Cresemba and Zevtera of CHF 75-85 million for the financial year 2018.
 
more...
 
Friday, January 04. 2019
 
Basel, Switzerland, January 04, 2019 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that David Veitch, Chief Executive Officer of Basilea, will present at the 37th Annual J. P. Morgan Healthcare Conference on January 10, 2019 at 8:30 a.m. Pacific Standard Time / 5:30 p.m. Central European Time at the Westin St. Francis Hotel, San Francisco, CA.
 
more...
 
Info
 
 
 

Quick links:

Investor calendar
Upcoming events
 


News subscription
Press releases via e-mail
 


French Sunshine Act
Transparence des liens d’intérêt